174 related articles for article (PubMed ID: 36989812)
21. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.
Popowicz GM; Czarna A; Wolf S; Wang K; Wang W; Dömling A; Holak TA
Cell Cycle; 2010 Mar; 9(6):1104-11. PubMed ID: 20237429
[TBL] [Abstract][Full Text] [Related]
22. Regulation of p53: a collaboration between Mdm2 and Mdmx.
Pei D; Zhang Y; Zheng J
Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
[TBL] [Abstract][Full Text] [Related]
23. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
[TBL] [Abstract][Full Text] [Related]
24. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
[TBL] [Abstract][Full Text] [Related]
25. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
Barakat K; Mane J; Friesen D; Tuszynski J
J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
[TBL] [Abstract][Full Text] [Related]
26. Mdmx promotes genomic instability independent of p53 and Mdm2.
Carrillo AM; Bouska A; Arrate MP; Eischen CM
Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
[TBL] [Abstract][Full Text] [Related]
27. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z
Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542
[TBL] [Abstract][Full Text] [Related]
28. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
29. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
Cai X; Yuan ZM
J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
[TBL] [Abstract][Full Text] [Related]
30. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
[TBL] [Abstract][Full Text] [Related]
31. Inferring Leading Interactions in the p53/Mdm2/Mdmx Circuit through Live-Cell Imaging and Modeling.
Heltberg ML; Chen SH; Jiménez A; Jambhekar A; Jensen MH; Lahav G
Cell Syst; 2019 Dec; 9(6):548-558.e5. PubMed ID: 31812692
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
33. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
34. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, and
Alimujiang Y; Maimaiti A; Ablise M; Yang Z; Liu Z; Wang Y; Mutalipu Z; Yan T
Anticancer Agents Med Chem; 2024; 24(6):423-435. PubMed ID: 38204258
[TBL] [Abstract][Full Text] [Related]
36. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
37. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
38. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
39. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
Wang X
Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
[TBL] [Abstract][Full Text] [Related]
40. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]